Gemcitabine Injection IP

Sharing Formulations Pvt Ltd is marketing Gemcitabine Injection IP 200 mg in India.

• Gemcitabine is S-Phase specific.
• It is deoxycytidine antimetabolite.
• Gemcitabine gets phosphorylated thrice and gets converted to gemcitabine triphosphate which competes with deoxycytidine triphostate for incorporation into DNA strand.
• As the addition of a base pair before DNA polymerase is stopped; Gemcitabine inhibits both DNA repair and replication resulting in apoptosis.

INDICATIONS :

• Pancreatic cancer
• Metastatic breast cancer
• Advanced non-small cell lung cancer
• Advanced ovarian cancer
• Bladder Cancer
• Soft tissue sarcoma